Vir Biotechnology
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2016-04-07
- Employees
- 587
- Market Cap
- -
- Website
- http://www.vir.bio
- Introduction
Vir Biotechnology, Inc. operates as a clinical-stage immunology company that focuses on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases. The firm's technology platforms include antibody, T cell, innate immunity and siRNA, which are designed to stimulate and enhance the immune system by exploiting critical observations of natural immune processes. The company was founded by Robert Taylor Nelsen, Klaus Frueh, Jay Parrish, Lawrence Corey, and Louis Picker in April 7, 2016 and is headquartered in San Francisco, CA.
Possible Bearish Signals With Vir Biotechnology Insiders Disposing Stock
Vir Biotechnology insiders sold shares over the past year, with no purchases, raising investor concerns. Insiders own 5.1% of the company, worth about $54m, suggesting reasonable alignment. The lack of recent insider transactions leaves investors cautious.
Vir Biotechnology Announces Clinical Advances Across Hepatitis Delta and Hepatitis B ...
Vir Biotechnology to present Phase 2 SOLSTICE trial data on tobevibart and elebsiran for chronic hepatitis delta at AASLD's The Liver Meeting, highlighting efficacy, safety, and economic burden insights.
Vir Biotechnology Announces Clinical Advances Across Hepatitis Delta and Hepatitis B
Vir Biotechnology presents Phase 2 SOLSTICE trial data on tobevibart and elebsiran for chronic hepatitis delta and B at AASLD's The Liver Meeting® in San Diego, November 15-19, 2024.
Vir Biotechnology Announces Clinical Advances Across Hepatitis Delta and ...
Vir Biotechnology to present Phase 2 SOLSTICE trial data on tobevibart and elebsiran for chronic hepatitis delta at AASLD's The Liver Meeting, highlighting efficacy, safety, and economic burden.
Vir Biotechnology to present hepatitis trial findings
Vir Biotechnology to present Phase 2 SOLSTICE trial data at AASLD, evaluating tobevibart and elebsiran for chronic hepatitis delta. The company aims to improve patient outcomes and advance a functional cure for chronic hepatitis B. Recent developments include FDA approval for an Investigational New Drug application and a Fast Track designation for a novel combination treatment. Vir's financial health presents mixed signals, with more cash than debt but significant revenue decline.
Vir Biotechnology, Inc. (NASDAQ:VIR) is largely controlled by institutional shareholders who ...
Institutional ownership of Vir Biotechnology is 53%, influencing stock price sensitivity. Six major investors hold a majority stake. Ownership research and analyst forecasts aid in understanding stock opportunities. Insider ownership is present, aligning with shareholder interests. General public and private equity also hold significant stakes, with public companies owning 6.3%. Analyst forecasts and potential warning signs are crucial for future insights.
Algert Global LLC Purchases New Position in Vir Biotechnology, Inc. (NASDAQ:VIR)
Algert Global LLC bought 166,835 shares of Vir Biotechnology in Q2, valued at $1.485M. Other investors also increased their holdings, with 65.32% of the stock owned by institutions. Director Janet Napolitano sold 12,190 shares at $7.80 each, owning 11,616 shares post-sale. Vir Biotechnology's stock opened at $7.33, with a market cap of $997.31M. The company reported a Q2 loss of $1.02 per share, missing estimates by $0.13. Analysts predict a -3.26 EPS for the current fiscal year, with an average target price of $36.80.
Vir Biotechnology to Participate in the H.C. Wainwright 5th Annual Viral Hepatitis Virtual Conference
Vir Biotechnology announces Mark Eisner's participation in a fireside chat at the H.C. Wainwright 5th Annual Viral Hepatitis Virtual Conference on Oct 8, 10:00 a.m. PT / 1:00 p.m. ET. A live webcast will be available on the Vir website and archived for 30 days.
© Copyright 2024. All Rights Reserved by MedPath